| Registry | NCT02589340, acronym BUS-PD |
|---|---|
| Status | Terminated - Low enrollment |
| Phase | Phase 1 |
| Study type | Interventional; randomized, crossover, masking: quadruple, treatment |
| Enrollment | 6 (Actual) |
| Sponsor | Oregon Health and Science University (Other); collaborators: Portland VA Medical Center |
| Conditions | Parkinson's Disease, Dyskinesias, Movement Disorders |
| Interventions | Buspirone, Placebo (Drug) |
| Dates | start 2016-01-01, primary completion 2021-02-23, completion 2021-02-23, first posted 2015-10-28, last updated 2021-03-05 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Parkinson's Disease All trials for Dyskinesias All trials of Buspirone All trials of Placebo
The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
Plan: We will perform a randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for LID in PD.
Methods: Eligible subjects who consent to participate in this study will be randomized to one of two sequences of treatment interventions during the baseline visit. Each treatment sequence includes placebo and buspirone interventions. After randomization, each participant will titrate up on study drug for two weeks ending in 30 mg/day. At the end of each two week study drug period, the participant will then have a study visit at the VA Portland Health Care System that includes safety monitoring, adverse event monitoring, drug compliance, and several measurements of LID.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Buspirone | Experimental | Drug: Buspirone | Two week titration up to 10 mg tablet/3 times a day for 7 days |
| Placebo | Placebo comparator | Drug: Placebo | Two week titration up to 3 tablets/3 times a day for 7 days |
Sex: All, ages: 18 Years to 99 Years
Inclusion Criteria: * Parkinson's disease diagnosis * Currently taking a levodopa containing medication for Parkinson's disease * Mild to Severe dyskinesia * Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia. * Stable medication regimen for at least 4 weeks prior to study. Exclusion Criteria: * Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation. * Not able to follow verbal commands * Not able to stand unsupported for at least 60 seconds * Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia. * Have proprioceptive deficits. * Have a history of hepatic impairment * Currently have severe renal impairment * Currently have any other medical or psychiatric diagnosis that would preclude their ability to safely participate in the study. * Significant cognitive impairment * Pregnancy * Breast-Feeding * Unable to swallow study drug (capsule)
| Facility | City | Country | Status |
|---|---|---|---|
| VA Portland Health Care System | Portland, Oregon | United States |